S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
Is This The End of Capitalism? (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
Is This The End of Capitalism? (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
Is This The End of Capitalism? (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
Is This The End of Capitalism? (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
NASDAQ:PODD

Insulet - PODD Stock Forecast, Price & News

$286.20
+0.70 (+0.25%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$283.00
$289.99
50-Day Range
$279.72
$313.00
52-Week Range
$181.00
$320.00
Volume
370,195 shs
Average Volume
349,475 shs
Market Capitalization
$19.88 billion
P/E Ratio
1,192.50
Dividend Yield
N/A
Price Target
$309.23

Insulet MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
9.0% Upside
$312.08 Price Target
Short Interest
Bearish
3.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.20
Upright™ Environmental Score
News Sentiment
0.57mentions of Insulet in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$8.51 M Sold Last Quarter
Proj. Earnings Growth
17.24%
From $0.87 to $1.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

561st out of 1,055 stocks

Surgical & Medical Instruments Industry

58th out of 106 stocks


PODD stock logo

About Insulet (NASDAQ:PODD) Stock

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock News Headlines

Insulet Has Potential To Gain More Than Analysts Are Forecasting
Even as it pulled back with the broader market Tuesday, insulin pump maker Insulet found support along its 50-day line and remained in possible buy range.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Insulet's (PODD) Omnipod Sales Aid, Costs Continue to Rise
Is Insulet About to Continue Its Move Higher?
2 Best Medical Device Stocks for 2023
Why Insulet Stock Is Skyrocketing Today
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Company Calendar

Last Earnings
11/03/2022
Today
1/31/2023
Next Earnings (Confirmed)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,300
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$312.08
High Stock Price Forecast
$345.00
Low Stock Price Forecast
$245.00
Forecasted Upside/Downside
+8.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
13 Analysts

Profitability

Net Income
$16.80 million
Pretax Margin
1.68%

Debt

Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$1.08 per share
Book Value
$8.07 per share

Miscellaneous

Free Float
68,824,000
Market Cap
$19.88 billion
Optionable
Optionable
Beta
0.79

Social Links


Key Executives

  • James R. Hollingshead
    President, Chief Executive Officer & Director
  • Prem Singh
    Senior Vice President-Global Operations
  • Wayde Dwight McMillan
    Chief Financial Officer, Treasurer & Executive VP
  • Trang Ly
    Senior Vice President & Medical Director
  • Michael P. Spears
    Senior VP-Quality, Regulatory Affairs & Compliance













PODD Stock - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price forecast for 2023?

13 brokerages have issued 1-year target prices for Insulet's shares. Their PODD share price forecasts range from $245.00 to $345.00. On average, they anticipate the company's stock price to reach $312.08 in the next year. This suggests a possible upside of 9.0% from the stock's current price.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2023?

Insulet's stock was trading at $294.39 at the start of the year. Since then, PODD shares have decreased by 2.8% and is now trading at $286.20.
View the best growth stocks for 2023 here
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PODD earnings forecast
.

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Thursday, February 23rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Thursday, November, 3rd. The medical instruments supplier reported $0.45 EPS for the quarter, beating the consensus estimate of $0.17 by $0.28. The medical instruments supplier earned $340.80 million during the quarter, compared to analyst estimates of $311.84 million. Insulet had a net margin of 1.35% and a trailing twelve-month return on equity of 18.19%.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $341.55 million-$350.78 million, compared to the consensus revenue estimate of $328.46 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.65%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), AEGON ASSET MANAGEMENT UK Plc (0.27%), Beacon Investment Advisory Services Inc. (0.27%), Scout Investments Inc. (0.22%) and New York State Common Retirement Fund (0.14%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, Dan Manea, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends
.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $286.20.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $19.88 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.24 on an earnings per share basis.

How many employees does Insulet have?

The company employs 2,300 workers across the globe.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 1/31/2023 by MarketBeat.com Staff